European Medicines Agency issues advice on use of Paxlovid (PF-07321332 and ritonavir) for the treatment of COVID-19

The CHMP has recommended Paxlovid (not yet authorised) can be used to treat adults who do not require supplemental oxygen and who are at increased risk of progressing to severe disease. It should be administered as soon as possible and within 5 days of the start of symptoms.

SPS commentary:

The EMA has issued this advice to support national authorities who may decide on possible early use of the medicine prior to marketing authorisation. It is based on interim results from a study in non-hospitalised, unvaccinated patients who had symptomatic disease and at least one underlying condition putting them at risk of severe COVID-19.

PF-07321332 is designed to block the activity of the SARS-CoV-2-3CL protease, an enzyme that the coronavirus needs to replicate. Co-administration with a low dose of ritonavir helps to slow its metabolism.

European Medicines Agency